Starpharma Holdings Ltd (ASX: SPL) has seen its stock price more than double in September 2023, driven by significant developments in its collaboration with Radiopharm Theranostics Ltd (ASX: RAD). The biotechnology company’s shares rose by 13.6% in early trading, reaching 25 cents, compared to a starting price of 12 cents at the beginning of the month. Over the past year, the stock has shown remarkable growth, with a low of 8.2 cents per share.
Strategic Partnerships Drive Growth
On September 12, Starpharma announced a research and option agreement with Radiopharm, marking a pivotal moment in its business strategy. After six months of preliminary research, this collaboration will see Starpharma utilize its proprietary DEP platform technology to develop a dendrimer-drug conjugate. This product will incorporate a radiopharmaceutical molecule under development by Radiopharm.
As part of this agreement, Starpharma is set to receive various financial incentives, including a $500,000 option fee, a $2 million upfront payment, and the potential for up to $89 million in success-based milestones and royalties on net sales. This partnership represents the first radiopharmaceutical collaboration for Starpharma and the initial advancement of its Star Navigator program into formal research.
In addition to the Radiopharm partnership, Starpharma recently finalized another significant deal with Genentech, a major player in the pharmaceutical sector. This agreement, which has been in negotiation for three years, could yield success payments totaling up to USD $564 million (approximately AUD $857.4 million).
CEO Highlights Industry Validation
Starpharma’s Chief Executive Officer, Cheryl Maley, emphasized the importance of the Radiopharm agreement, stating it serves as external validation for the potential of dendrimers in radiopharmaceutical drug development. “Radiopharmaceuticals are a key area of focus for Starpharma. Our strategy involves developing high-value, differentiated assets and forming strategic partnerships, all supported by robust scientific data,” Maley noted.
Over the past year, Starpharma has focused on optimizing its internal DEP radiotheranostics program and has actively showcased its dendrimer technology at various scientific conferences. These efforts have attracted industry interest and opened new collaboration opportunities.
Riccardo Canevari, CEO of Radiopharm Theranostics, commented on the evolving landscape of targeted radiotherapeutics, expressing enthusiasm for the partnership. “We are committed to exploring different and innovative options that have the potential to improve the efficacy and safety of new radiopharmaceutical vectors. We are excited by the opportunity to work with the capable team of Starpharma to pursue this important and ambitious goal,” Canevari said.
In response to these developments, Radiopharm’s shares fell by 3.4% to 2.8 cents, reflecting market fluctuations that often accompany significant partnership announcements.
As Starpharma continues to cultivate its partnerships and expand its product offerings, the market will be watching closely to see how these collaborations impact its growth trajectory. The company is firmly positioned in the biotechnology sector, and its recent agreements may pave the way for further advancements in radiopharmaceutical technology.
